Supercharged MSCs (E-selectin)
Rare Vascular Ischemia
Pre-clinicalActive
Key Facts
About Ambulero
Ambulero is a private, preclinical-stage biotechnology company leveraging a novel platform based on the therapeutic delivery of E-selectin to combat vascular disease. The company is advancing two core modalities: engineered 'supercharged' mesenchymal stromal cells (MSCs) and an AAV-based gene therapy, both designed to stimulate blood vessel growth and tissue repair. Initially targeting a rare form of vascular ischemia with high unmet need, Ambulero's technology is built on over a decade of NIH-funded academic research from its scientific founders. The company is led by a team with experience in entrepreneurship, drug development, and vascular surgery.
View full company profileTherapeutic Areas
Other Rare Vascular Ischemia Drugs
| Drug | Company | Phase |
|---|---|---|
| AAV Gene Therapy (E-selectin) | Ambulero | Pre-clinical |